Barron's Take

A new set of provisions takes away tax credits if a project relies on China for any part of its clean-energy-supply chain.

Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday on a rival’s study.

Planet Labs reports breakeven adjusted first-quarter earnings, beating expectations. Free cash flow is now in the black.

High-end consumers are turning to cheaper alternatives in the face of weaker economic data. “It’s not the time to freak out,” says one observer.

For investors, the Trump-Musk budget spat risks taking the focus of robotaxis.

Rising bond yields could be a problem for countries looking to spend more and lower taxes. President Donald Trump will need to take note.

Worries expressed by JPMorgan Chase CEO Jamie Dimon appear to be shared by plenty of executives across the country.

After an early stumble, the S&P 500 index has gone on to set new highs later in every year since 1980, except for one. 

Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.

“Overall, the weight of the technical evidence suggests this recovery is real,” LPL Financial’s Jeffrey Buchbinder notes.

Staples, utilities, and healthcare have fallen out of favor since President Donald Trump’s tariff reversal. They could be ready to rally.

The company doing business as Strategy says it acquired 705 Bitcoins for $75.1 million.

President Donald Trump insists that parts for U.S.-made cars should be made in America. The effort would be greater than a sum of the parts.

Ukraine’s “Operation Spiderweb” will have defense analysts examining drone tactics and defense systems in the coming months.

Tesla is set to launch its highly anticipated robotaxi service this month. Will that drive shares higher or will investors take profits now that the seminal event has arrived?

Gavekal Founding Partner and Head of Research Arthur Kroeber notes, “The overall objectives of the trade aggression...are as muddled as ever.

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

Investors flocked to shares of NRG as the energy supplier boosted capacity. UnitedHealth stock slumped, and the company’s CEO resigned.

“Float like a butterfly, sting like a bee,” Muhammad Ali used to say. “The hands can’t hit what the eyes can’t see.”

Uber stock dropped ahead of Tesla’s Robotaxi rollout, and now shares have even more upside.

Trump Media announced plans to acquire $2.5 billion in Bitcoin as it looks to follow the MicroStrategy playbook.

Europe’s stocks are beating the U.S. this year—and they’ve been less volatile, too.

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Warren Buffett surprised investors at the May 3 Berkshire Hathaway annual meeting with plans to give up the CEO job at the end of 2025.

The company can recover if its CEO takes his medicine.